CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $9.42B, above the global median of $1.18B
- PositionReturn on equity is 25%, higher than 95% of its Medical Devices peers (median 3.7%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.42BUSDvs all stocks (USD)
Trailing P/E
44.43xvs Medical Devices peers
Revenue (TTM)
1.56BUSDvs all stocks (USD)
Profit Margin
4.90%vs Medical Devices peers
Beta
1.10xvs all stocks
52-Week Change
8.94%vs all stocks
Market Capitalization
9.42BUSDvs all stocks (USD)
Enterprise Value
9.78BUSDvs all stocks (USD)
Trailing P/E
44.43xvs Medical Devices peers
Forward P/E
26.84xvs Medical Devices peers
PEG Ratio
-0.3299xvs Medical Devices peers
Price to Sales (TTM)
6.05xvs Medical Devices peers
Price to Book (MRQ)
11.94xvs Medical Devices peers
Enterprise to Revenue
6.28xvs Medical Devices peers
Enterprise to EBITDA
26.61xvs Medical Devices peers
Gross Margin
62.14%vs Medical Devices peers
Profit Margin
4.90%vs Medical Devices peers
Operating Margin
23.61%vs Medical Devices peers
Return on Assets (TTM)
10.20%vs Medical Devices peers
Return on Equity (TTM)
24.99%vs Medical Devices peers
Revenue (TTM)
1.56BUSDvs all stocks (USD)
Revenue per Share (TTM)
29.32USDUpdated Jul 9, 2026Quarterly Revenue Growth
8.50%vs Medical Devices peers
Gross Profit (TTM)
960.50MUSDvs all stocks (USD)
EBITDA (TTM)
350.80MUSDvs all stocks (USD)
Net Income (TTM)
216.80MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
232.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
327.92MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.53BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
581.70MUSDFY2025 · Dec 31, 2025Gross Profit
945.20MUSDFY2025 · Dec 31, 2025Operating Income
312.80MUSDvs all stocks (USD)
Pre-tax Income
272.60MUSDFY2025 · Dec 31, 2025Income Tax Expense
64.90MUSDFY2025 · Dec 31, 2025Net Income
-151.50MUSDFY2025 · Dec 31, 2025EBIT
305.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
355.00MUSDFY2025 · Dec 31, 2025Research & Development
126.40MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
506.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.40MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
33.20MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.83USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.83USDFY2025 · Dec 31, 2025Basic Shares Outstanding
53.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
53.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
207.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
198.40MUSDFY2025 · Dec 31, 2025Free Cash Flow
198.20MUSDDerived from operating cash flow minus capital expenditure. This filing charges 38.8M of depreciation against 200K of capital expenditure, and its own free-cash-flow line reads 193.1M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
153.30MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
207.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
38.80MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
11.80MUSDFY2025 · Dec 31, 2025Stock-based Compensation
35.80MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
17.20MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-27.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-88.80MUSDFY2025 · Dec 31, 2025Capital Expenditures
200.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-5.30MUSDFY2025 · Dec 31, 2025Other Investing Activity
1.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
1.90MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.28BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-204.10MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-363.70MUSDFY2025 · Dec 31, 2025Other Financing Charges
-21.70MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.80BUSDFY2025 · Dec 31, 2025Shares Outstanding
52.36MSharesUpdated Jul 9, 2026Float Shares
44.31MSharesUpdated Jul 9, 2026Shares Short
3.50MSharesUpdated Jul 9, 2026Short Ratio
3.84daysvs all stocks
Short % of Shares Outstanding
7.34%vs all stocks
% Held by Insiders
6.21%vs all stocks
% Held by Institutions
104.78%vs all stocks
Total Cash (MRQ)
124.60MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.38USDUpdated Jul 9, 2026Total Debt (MRQ)
485.90MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6159xvs Medical Devices peers
Current Ratio (MRQ)
2.67xvs Medical Devices peers
Book Value per Share (MRQ)
15.06USDUpdated Jul 9, 2026Total Assets
1.70BUSDvs all stocks (USD)
Total Current Assets
926.00MUSDFY2025 · Dec 31, 2025Total Liabilities
977.70MUSDFY2025 · Dec 31, 2025Total Non-current Assets
772.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
606.10MUSDFY2025 · Dec 31, 2025Total Current Liabilities
371.60MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
152.30MUSDFY2025 · Dec 31, 2025Accounts Receivable
260.90MUSDFY2025 · Dec 31, 2025Inventory
380.30MUSDFY2025 · Dec 31, 2025Accounts Payable
103.00MUSDFY2025 · Dec 31, 2025Short-term Debt
14.40MUSDFY2025 · Dec 31, 2025Deferred Revenue
38.50MUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.70MUSDFY2025 · Dec 31, 2025Long-term Debt
544.90MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
7.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
100.00KUSDFY2025 · Dec 31, 2025Retained Earnings
1.34BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
721.20MUSDvs all stocks (USD)
Treasury Stock
1.53BUSDFY2025 · Dec 31, 202552-Week Low
125.94USDUpdated Jul 9, 202652-Week High
179.99USDUpdated Jul 9, 202652-Week Change
8.94%vs all stocks
Beta
1.10xvs all stocks
50-Day MA
178.69USDUpdated Jul 9, 2026200-Day MA
156.66USDUpdated Jul 9, 2026Avg 10-Day Volume
854.38KSharesUpdated Jul 9, 2026Avg 30-Day Volume
901.05KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
4.05USDUpdated Jul 9, 2026Other Income / Expense
-10.40MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 25%, higher than 95% of its Medical Devices peers (median 3.7%)Significant
Return on equity: 0.25Industry median: 0.04Industry P95: 0.18Peers compared: 60.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.62Profit Margin: 0.05
Financial Health
Altman Z-Score 8.77: safe zoneNotable
Altman Z-Score: 8.77
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $9.42B, above the global median of $1.18BNotable
Market cap (USD): 9,423,817,025Global Median: 1,179,398,897.704
Revenue is $1.56B, above the global median of $534.05MNotable
Revenue (USD): 1,558,499,968Global Median: 534,052,387.958
Levered free cash flow is $327.92M, above the global median of $19.19MNotable
Levered free cash flow (USD): 327,924,992Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Immunovant Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nuvalent, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Insulet Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jayaswal Neco Industries Ltd.
2 interpretationsThree Asset-Base Ratios ElevatedFCF Ratios Elevated
Abercrombie & Fitch Co.
2 interpretationsThree Asset-Base Ratios ElevatedFCF Ratios Elevated
Medpace Holdings Inc.
2 interpretationsThree Asset-Base Ratios ElevatedFCF Ratios Elevated